Epoch 7: Pharma Venture Capital Remains Steady

Big Pharma Venture Capital, Financing, Comps

Welcome to the 31 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1080 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. We are now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays.  

This week we discuss corporate venture capital.  In biopharma this essentially refers to the big pharma VC arms.  Recently the Global Corporate Venturing group shared the latest statistics on activity of corporate VC. There are a number of interesting take-aways to share, a handful of particular relevance to the role of corporate VC groups in today's difficult funding environment.

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

Note: Star Wars fans will recall in the first movie while Luke is positioning himself to deploy his last missile to blow up the Death Start his wingman is whispering in his ear “steady….steady…..” That is the inspiration for the picture below ha! CVC holding STEADY!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts.  This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences.  We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction.  Be sure to SUBSCRIBE to not miss.

Enough shilling for the day, lots to cover this week, let's get started!